NASDAQ

Updated Oct 30, 8:33 AM ET

NVCR

NovoCure Limited

−$1.06 (7.48%) Thu · Closed $13.11

−$0.19 (1.45%) ☀ Pre-Market

Oct 30, 8:33 AM ET

About NVCR

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Board

0 member threads · 0 replies

cylvex.com/s/NVCR

Community opinions, not advice. Posts with a target get a receipt. How receipts work ›